Report from the 27th Conference on Retroviruses and Opportunistic Infections (CROI) 2020
OK, so you all are probably wondering if I’m obsessed with long-acting therapies after the previous article and several others in this collection.
At the Conference on Retroviruses and Opportunistic Infections in March 2020, the top HIV research conference (held virtually), some new research looks very encouraging for what could be an important treatment.
It belongs to a brand new class of drugs called Capsid Inhibitors that work differently from all of the available HIV medicines.
Capsid is a specialized protein that envelopes the HIV genetic material.
Capsid inhibitors can block the release of the HIV’s genetic material (viral RNA) so it cannot replicate.